Transfusion therapy evidence-based recommendations for the pediatric cancer patient

  • Carlos Alberto Pardo-González Oncohematologist Pediatrician, Fundación Hospital de la Misericordia, Bogotá, D.C., Colombia
  • Adriana Linares a. Oncohematologist Pediatrician, Fundación Hospital de la Misericordia, Bogotá, D.C., Colombia. b. Associate Professor, Department of Pediatrics, Universidad Nacional de Colombia, Bogotá, D.C., Colombia
  • Marcela Torres Health Technologies and Policies Evaluation Team, School of Medicine, Universidad Nacional de Colombia, Bogotá, D.C., Colombia
Keywords: Blood transfusion, Blood substitutes, Blood platelets, Pediatrics, Review.


Introduction: Transfusion therapy is probably one of the most widely used therapies with poor supporting evidence, despite the long years of practical clinical use. 

Objective: To adapt the evidence-based recommendations on the use of blood products to the Colombian setting: red blood cells, platelets, cryoprecipitates and irradiated blood products in cancer patients under 18 years of age.

Methods: Standard methodologies were followed in the development of recommendations. First, the clinical questions were addressed, and the evidence-based clinical practice guidelines were identified, graded and selected to answer the clinical questions. A systematic methodology was used to qualify, obtain and describe the relevant information to generate recommendations based on the SIGN system. The results were then presented and discussed in a group of experts to establish the practical value of the evidence and to adapt the recommendations to the Colombian environment.

Results: Out of 107,441 preliminary titles, 56 studies were analyzed, and from them 3 clinical practice guidelines and 4 Cochrane systematic reviews were selected. This evidence was evaluated using AGREE II and AMSTAR. Red blood cells transfusion support is recommended using the restrictive strategy. Prophylactic platelet transfusion is the recommended indication. Cryoprecipitate is recommended when fibrinogen levels fall below 100mg/dL, and indications on irradiated blood products were established.

Conclusion: This paper is an evidence-base approach on the recommendations for transfusion therapy in children with cancer.


1. Repetto L, Moeremans K, Annemans L. European guidelines for the management of chemotherapy-induced anaemia and health economic aspects of treatment. Cancer Treat Rev. 2006;32 Suppl. 2:S5-9.
2. OPS: Organización Panamericana de la Salud, Oficina Regional para Las Américas. Plan de acción para el acceso universal a sangre segura, 154a sesión del comité ejecutivo Internet. Washington D.C.: OPS; 2014 cited 20.11.15. Available at:
3. MINISTERIO DE SALUD Y PROTECCIÓN SOCIAL, REPÚBLICA DE COLOMBIA. Política Nacional de sangre Internet. Bogotá: MinSalud y Protección Social; 2006 cited 16.11.15. Available at:
4. Carson J, Grossman B, Kleinman S, Tinmouth A, Marques M, Fung M, et al. Red blood cell transfusion: a clinical practice guideline from the AABB. Ann Intern Med. 2012;157:50-9.
5. Carrasquilla G, Bossert T, Quintero J, Mieth K, Guerrero R, Sánchez R, et al. Guía metodológica para la elaboración de guías de atención integral en el sistema general de seguridad social en salud Colombiano Internet. Bogotá: Ministerio de la Protección Social/Fundación Santa Fe de Bogotá; 2010 cited 16.11.15. Available at:
6. The AGREE Collaboration. AGREE Instrument Spanish Internet. Vitoria (País Vasco): Osteba; 2001 cited 15.11.15. Available at:
7. Preston N, Hurlow A, Brine J, Bennett M. Blood transfusions for anaemia in patients with advanced cancer. Cochrane Database Syst Rev. 2012;15:1-9.
8. Wilson J, Yao G, Raftery J, Bohlius J, Brunskill S, Sandercock J, et al. A systematic review and economic evaluation of epoetin alpha, eopoetin beta and darbopoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess. 2007;11:1-202.
9. Fasano R, Luban N. Blood component therapy. Pediatr Clin North Am. 2008;55:421-45.
10. Ministry of Health, Singapore Internet. HSA - MOH Clinical practice guidelines: Clinical Blood Transfusion. Singapore: MOH; 2011 cited 15.11.15. Available at:
11. Pozo A, Kuperman S, Benzadon R, Fernandez J, Kiman R, Komar D, et al. Guías Nacionales para el uso apropiado de la sangre y sus componentes. Rev argent Transfus. 2011;33:285-315.
12. Carson J, Carless P, Hebert P. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion (Review). Cochrane Database Syst Rev. 2012;18:CD002042.
13. Klaus S, Frank S, Salazar J, Cooper S, Beard L, Abdullah F, et al. Hemoglobin thresholds for transfusion in pediatric patients at a large academic health center. Transfusion. 2015;55:2890-7.
14. Couture F, Turner A, Melosky B, Xiu L, Plante R, Lau C, et al. Prior red blood cell transfusions in cancer patients increase the risk of subsequent transfusions with or without recombinant human erythropoietin management. Oncologist. 2005;10:63-71.
15. National Clinical Guideline Centre (UK). Blood transfusion. London: National Institute for Health and Care Excellence (UK); 2015.
16. Parker R. Transfusion in critically ill children: indications, risks, and challenges. Crit Care Med. 2014;42:675-90.
17. Simancas D, Osorio D, Martí A, Arevalo I. Leukoreduction for the prevention of adverse reactions from allogeneic blood transfusion. Cochrane Database Syst Rev. 2015;12:CD009745.
18. Estcourt L, Stanworth S, Doree C, Hopewell S, Murphy M, Tinmouth A, et al. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation. Cochrane Database Syst Rev. 2012;5:CD004269.
19. Barnard D, Portwine C, Sung L, Dupuis L, Romanick M, Erdmann G, et al. Guideline for platelet transfusion thresholds for pediatric hematology/oncology patients. Edmonton, Alberta: C17 Council; 2011. p. 55.
20. Chairman J, Atterbury C, Bolton M, Murphy M, Thomas D, Yates S, et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol. 2004;126:11-28.
21. Tinegate H, Allard S, Grant C, Hennem S, Kilner M, Rowley M, et al. Cryoprecipitate for transfusion: which patients receive it and why? A study of patterns of use across three regions in England. Transfus Med Rev. 2012;22:356-61.
22. Nascimento B, Goodnough L, Levy J. Cryoprecipitate therapy. Br J Anaesth. 2014;113:922-34.
23. Treleaven J, Gennery A, Marsh J, Norfolk D, Page L, Parker A, et al. Guidelines on the use of irradiated blood components prepared by the British Committee for Standards in Haematology blood transfusion task force. Br J Haematol. 2011;152:35-51.
24. Szczepiorkowski Z, Dunbar N. Transfusion guidelines: when to transfuse. Hematol Am Soc Hematol Educ Program. 2013;2013:638-44.
How to Cite
Pardo-González CA, Linares A, Torres M. Transfusion therapy evidence-based recommendations for the pediatric cancer patient. Colomb. J. Anesthesiol. [Internet]. 2016Apr.1 [cited 2021May12];44(2):151–160. Available from:


Download data is not yet available.
How to Cite
Pardo-González CA, Linares A, Torres M. Transfusion therapy evidence-based recommendations for the pediatric cancer patient. Colomb. J. Anesthesiol. [Internet]. 2016Apr.1 [cited 2021May12];44(2):151–160. Available from:
Clinical Practice Guides